BioPharma Resources

Drug Trial Radar · NCT06101329

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)

A Phase 2, Open-label, Multicenter, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Acceptability of Twice Yearly Long-acting Subcutaneous Lenacapavir for Pre-Exposure Prophylaxis in Cisgender Women in the United States

Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 253 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

253

Actual

Start

Nov 17, 2023

Primary completion

Jul 22, 2026

Study completion Jan 2028

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
Collaborators
HIV Prevention Trials Network
First posted
Oct 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to look at how lenacapavir (LEN) passes through the body and to assess the safety of LEN and emtricitabine/tenofovir disoproxil fumarate (F/TDF) for prevention of HIV in the cisgender women in the US. The primary objectives of this study are: 1) to characterize the pharmacokinetics (PK) of LEN in United States (US) cisgender women; 2) to evaluate the safety of LEN and F/TDF for pre-exposure prophylaxis (PrEP) in US cisgender women; and 3) to evaluate the general acceptability of LEN injections and oral F/TDF in US cisgender women.

Conditions

  • Pre-Exposure Prophylaxis of HIV Infection

Interventions

  • Lenacapavir TabletDrug

    Tablets administered orally without regard of food

  • Lenacapavir InjectionDrug

    Injection administered subcutaneously

  • Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)Drug

    200/300mg fixed dose combination (FDC) tablets administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic (PK) Parameter: Ctrough for Lenacapavir (LEN) at the End of Week 26Time frame: Week 26
  2. PK Parameter: Ctrough for LEN at the End of Week 52Time frame: Week 52
  3. Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)Time frame: First dose date up to 30 days post last dose at Week 78
  4. Percentage of Participants Experiencing Treatment-emergent Clinical Laboratory AbnormalitiesTime frame: First dose date up to 30 days post last dose at Week 78
  5. General Acceptability of LEN and F/TDF as PrEP as Assessed by Percentage of Participants with Acceptability Questionnaire ResponsesTime frame: Up to Week 52
  6. Satisfaction With Use of LEN and F/TDF as PrEP as Assessed by Percentage of Participants with Satisfaction Questionnaire ResponsesTime frame: Up to Week 52
  7. Willingness to Use LEN and F/TDF as PrEP as Assessed by Percentage of Participants with Willingness to Use Questionnaire ResponsesTime frame: Up to Week 52

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • UAB, 1917 Research Clinic

    Birmingham, Alabama

  • UCSD Antiviral Research Center (AVRC)

    San Diego, California

  • George Washington University Medical Faculty Associates

    Washington D.C., District of Columbia

  • Ponce de Leon Center Clinical Research Site

    Atlanta, Georgia

  • Fenway Health

    Boston, Massachusetts

  • Rutgers New Jesey Medical School - Clinical Research Center

    Newark, New Jersey

  • Cornell Clinical Trials Unit, New York Presbyterian Hospital - Weill Cornell Medicine

    New York, New York

  • Harlem Prevention Center CRS

    New York, New York

  • ICAP at Columbia University - Bronx Prevention Center

    The Bronx, New York

  • NC TraCS Institute - CTRC; University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Penn Prevention Research Unit

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.